Welcome to IFMAD Survey Questionnaire about digital therapeutics
Otsuka Pharmaceutical Europe Ltd. is conducting a survey to explore healthcare professionals’ use of digital therapeutics in managing depressive disorders. Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Our 34,400 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology and immunology, haemato-oncology, infectious diseases and digital therapeutics. We truly value your expertise and would greatly appreciate your input on this important initiative.
Otsuka Pharmaceutical Europe Ltd is a sponsor of IFMAD Conference 2025.
This survey questionnaire has been developed and funded by Otsuka Pharmaceutical Europe Ltd. It is intended for healthcare professionals only.
Lena Corporation S.A.M. – Lena Group
Job code: OPE-DM-2500023 (v1.0). Date of preparation: April 2025
CME accreditation
The 20th International Forum on Mood and Anxiety Disorders, Budapest, Hungary, 04/06/2025 – 06/06/2025 organized by AFISM – Association Internationale pour la promotion de Formations Specialisees en Medecine et en Sciences Biologiques has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 13.0 European CME credits (ECMEC®s).